Humacyte outlines 12-month cash runway and accelerates Symvess adoption following $56.5M capital raise
Source: SeekingAlpha
2025-11-12 12:22:21 ET
More on Humacyte
- Humacyte, Inc. (HUMA) Q3 2025 Earnings Call Transcript
- Humacyte: Shares Tank On Fundraising News - What You Need To Know
- Humacyte Q3 2025 Earnings Preview
- Humacyte shares sink as it announces pricing of $60M direct offering
- Seeking Alpha’s Quant Rating on Humacyte
Read the full article on Seeking Alpha
For further details see:
Humacyte outlines 12-month cash runway and accelerates Symvess adoption following $56.5M capital raise
Humacyte Inc.
NASDAQ: HUMA
HUMA Trading
4.03% G/L:
$1.265 Last:
4,307,770 Volume:
$1.22 Open:
HUMA Latest News
February 18, 2026 08:00:00 am
Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting
February 09, 2026 08:00:00 am
Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels
HUMA Stock Data
$220,166,898
198,988,939
0.6%
62
N/A
Biotechnology & Life Sciences
Healthcare
US
Durham
